Treatment of obesity and essential hypertension and related diso

Details Treatment of obesity and essential hypertension and related diso Treatment of obesity and essential hypertension and related diso

1991-07-18

1994-01-18

Lee, Lester L.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

514 4, 514 13, 514 14, 514 15, 514 16, 514 17, A61K 3702, C07K 710

Patent

active

052800148

ABSTRACT:
The administration of antagonists and blockers of amylin or CGRP or both for the treatment of obesity and essential hypertension and associated lipid disorders and atherosclerosis.

REFERENCES:
Proceedings of the National Academy of Sciences, Cooper et al., vol. 84, pp. 8628-8632, Dec. 1987.
Proceedings of the National Academy of Sciences, vol. 84, Westermark et al., pp. 3881-3885, Jun. 1987.

Affiliated with

Also associated with

Rating

Treatment of obesity and essential hypertension and related diso does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of obesity and essential hypertension and related diso, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of obesity and essential hypertension and related diso will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1136425